US Patents With Foreign Priority to Patent: 08164104
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VIJOICE | alpelisib | GRANULES;ORAL | 218466-001 | Apr 24, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | |||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-001 | May 24, 2019 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF ADULTS WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER | ||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-002 | May 24, 2019 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF ADULTS WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER | ||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-003 | May 24, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF ADULTS WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER | ||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-001 | Apr 5, 2022 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | |||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-002 | Apr 5, 2022 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | |||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-003 | Apr 5, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
